Phase 3 Study of Plozasiran in Adults With Hypertriglyceridemia (MUIR-3)
Double-blind, Placebo-controlled, Phase 3 Study to Evaluate the Efficacy and Safety of Plozasiran in Adults With Hypertriglyceridemia
Sponsor: Arrowhead Pharmaceuticals
This PHASE3 trial investigates Hypertriglyceridemia and is currently ongoing. Arrowhead Pharmaceuticals leads this study, which shows 13 recorded versions since 2024 — indicating substantial longitudinal coverage. The change history captured here reflects the iterative nature of clinical trial conduct.
Status Flow
Change History
13 versions recorded-
Nov 2025 — Present [monthly]
Active Not Recruiting PHASE3
-
Oct 2025 — Nov 2025 [monthly]
Active Not Recruiting PHASE3
-
Sep 2025 — Oct 2025 [monthly]
Active Not Recruiting PHASE3
-
Aug 2025 — Sep 2025 [monthly]
Active Not Recruiting PHASE3
Status: Recruiting → Active Not Recruiting
-
Apr 2025 — Aug 2025 [monthly]
Recruiting PHASE3
▶ Show 8 earlier versions
-
Mar 2025 — Apr 2025 [monthly]
Recruiting PHASE3
-
Dec 2024 — Mar 2025 [monthly]
Recruiting PHASE3
-
Nov 2024 — Dec 2024 [monthly]
Recruiting PHASE3
-
Oct 2024 — Nov 2024 [monthly]
Recruiting PHASE3
-
Sep 2024 — Oct 2024 [monthly]
Recruiting PHASE3
-
Jul 2024 — Sep 2024 [monthly]
Recruiting PHASE3
-
Jun 2024 — Jul 2024 [monthly]
Recruiting PHASE3
-
May 2024 — Jun 2024 [monthly]
Recruiting PHASE3
First recorded
Eligibility Summary
No eligibility information available.
Contact Information
- Arrowhead Pharmaceuticals
For direct contact, visit the study record on ClinicalTrials.gov .